Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
[EN] SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE SPIROCYCLIQUE SUBSTITUÉS EN TANT QUE LIGANDS DE RÉCEPTEUR D'HISTAMINE-3 (H3)
申请人:CEPHALON INC
公开号:WO2009097567A4
公开(公告)日:2009-10-29
SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS
申请人:Cephalon, Inc.
公开号:EP2250176B1
公开(公告)日:2012-08-01
Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands
申请人:Bacon Edward R.
公开号:US20110071131A1
公开(公告)日:2011-03-24
The present invention provides compounds of Formula (I):
their use as H
3
antagonists/inverse agonists, processes for their preparation, and pharmaceuticals compositions thereof.